Cyteir Therapeutics Inc (CYT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2014 | 12-2013 | 12-2012 | 12-2011 | 12-2010 | |
| Sales | 2,007,700 | 1,935,000 | 1,708,100 | 1,415,900 | 1,223,400 |
| Cost of Goods | 1,403,800 | 1,283,100 | 1,202,900 | 1,028,000 | 861,600 |
| Gross Profit | 603,900 | 651,900 | 505,200 | 387,900 | 361,800 |
| Operating Expenses | 371,000 | 342,600 | 373,900 | 280,100 | 248,900 |
| Operating Income | 233,700 | 309,400 | 132,200 | 107,800 | 113,500 |
| Interest Expense | 14,400 | 18,200 | 30,100 | 35,800 | 33,200 |
| Other Income | -29,100 | -47,200 | 1,100 | -4,200 | -6,700 |
| Pre-tax Income | 190,200 | 244,000 | 103,200 | 67,800 | 73,600 |
| Income Tax | 46,100 | 72,300 | 27,500 | 10,300 | 6,600 |
| Net Income Continuous | 144,100 | 171,700 | 75,700 | 57,500 | 67,000 |
| Net Income Discontinuous | 9,700 | 2,200 | 101,300 | 131,500 | 108,100 |
| Minority Interests | 0 | 400 | 2,100 | 3,100 | 2,800 |
| Net Income | $153,800 | $173,500 | $174,900 | $185,900 | $172,300 |
| EPS Basic Total Ops | 2.13 | 2.20 | 1.90 | 1.92 | 1.75 |
| EPS Basic Continuous Ops | 2.00 | 2.18 | 0.82 | 0.60 | 0.68 |
| EPS Basic Discontinuous Ops | 0.13 | 0.02 | 1.08 | 1.33 | 1.07 |
| EPS Diluted Total Ops | 2.09 | 2.16 | 1.87 | 1.90 | 1.73 |
| EPS Diluted Continuous Ops | 1.96 | 2.14 | 0.81 | 0.59 | 0.68 |
| EPS Diluted Discontinuous Ops | 0.13 | 0.02 | 1.06 | 1.31 | 1.06 |
| EBITDA(a) | $315,300 | $384,600 | $204,900 | $161,500 | $159,900 |